MET-X, a novel metallo-beta-lactamase (MBL) inhibitor, has shown best-in-class performance in preclinical studies
Zongertinib would be the first orally administered, targeted therapy for previously treated patients with HER2 (ERBB2)-mutant advanced non-small cell lung cancer (NSCLC), if approved
Dr. Prabhavathi brings over 14 years of unparalleled experience in pediatrics and a specialized focus on neurodevelopmental disorders
Imfinzi reduced the risk of distant metastases and death from bladder cancer vs. neoadjuvant chemotherapy alone
The safety profile of Opdualag observed in this analysis was consistent with the known profiles of nivolumab and relatlimab
Branded formulation business continues to perform well across domestic and export markets
These solutions combine scientifically or clinically validated, regulatory-approved probiotic strains with precise dosing
Based on DESTINY-Breast06 Phase III trial results which showed Enhertu demonstrated superiority vs. chemotherapy with a median progression-free survival of more than one year
The company ensures a reliable and strong portfolio at competitive prices without compromising on excellent quality
Regulatory filings underway for a third indication for darolutamide in prostate cancer, for finerenone in a common form of heart failure, and acoramidis in transthyretin amyloid
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
